Polycystic ovarian syndrome: a modern overview


如何引用文章

全文:

详细

Polycystic ovarian syndrome (PCOS) is one of the most common metabolic and reproductive disorders among women of reproductive age. Women suffering from PCOS have a whole complex of symptoms associated with menstrual dysfunction and androgen excess, which significantly impacts their quality of life. They may be at increased risk of multiple morbidities, including obesity, insulin resistance, type II diabetes mellitus, endometrial cancer, and psychological disorders. This review summarizes guidelines to diagnosis of PCOS, stress on the various aspects of treatment and screening recommendations currently used in the management of this condition.

作者简介

S Dubrovina

Rostov State Medical University of the Ministry of Health of the Russian Federation; Rostov Research Institute of Obstetrics and Pediatrics of the Ministry of Health of the Russian Federation

Email: s.dubrovina@gmail.com
д-р мед. наук, проф. каф. акушерства и гинекологии №1 ФГБОУ ВО РостГМУ, гл. науч. сотр. ФГБУ РНИИАП 344022, Russian Federation, Rostov-on-Don, per. Nakhichevanskii, d. 29; 344012, Russian Federation, Rostov-on-Don, ul. Mechnikova, d. 43

参考

  1. Fauser B.C, Tarlatzis B.C, Rebar R.W et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012; 97 (1): 28-38.e25.
  2. Ünlütürk U, Sezgin E, Yildiz B.O. Evolutionary determinants of polycystic ovary syndrome - part 1. 2016. Fertil Steril 2016; 106 (1): 33-41.
  3. Lauritsen M.P, Bentzen J.G, Pinborg A et al. The prevalence of polycystic ovary in a normal population according to the Rotterdam criteria versus revised criteria including anti - Mullerian hormone. Hum Reprod 2014; 29 (4): 791-80.
  4. El Hayek S, Bitar L, Hamdar L.H et al. Poly cystic ovarian syndrome: an updated overview. Front Physiol 2016; 7: 124.
  5. Bhide P, Homburg R. Anti Mullerian hormone and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2016. Accepted Manuscript.
  6. De Leo V, Musacchio M.C, Cappelli V et al. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol 2016; 14 (1): 38.
  7. Maliqueo M, Lara H.E, Sánchez F et al. Placental steroidogenesis in pregnant women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2013; 166 (2): 151-5.
  8. Jones M.E, Boon W.C, Mc Innes K et al. Recognizing rare disorders: aromatase deficiency. Nat Clin Pract Endocrinol Metab 2007; 3 (5): 414-21.
  9. Hertig A, Liere P, Chabbert-Buffet N et al. Steroid profiling in preeclamptic women: evidence for aromatase deficiency. Am J Obstet Gynecol 2010; 203 (5): 477.e1-9.
  10. Jobe S.O, Tyler C.T, Magness R.R. Aberrant synthesis, metabolism, and plasma accumulation of circulating estrogens and estrogen metabolites in preeclampsia implications for vascular dysfunction. Hypertension 2013; 61 (2): 480-7.
  11. Legro R.S, Kunselman A.R, Demers L et al. Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87 (5): 2134-8.
  12. Sam S, Sung Y.A, Legro R.S, Dunaif A. Evidence for pancreatic beta - cell dysfunction in brothers of women with polycystic ovary syndrome. Metabolism 2008; 57 (1): 84-9.
  13. Jones M.R, Goodarzi M.O. An update on the genetics of polycystic ovary syndrome: progress and future directions. Fertil Steril 2016. Article in press.
  14. Cui L, Li G, Zhong W et al. Polycystic ovary syndrome susceptibility single nucleotide polymorphisms in women with a single PCOS clinical feature. Hum Reprod 2015; 30 (3): 732-6.
  15. Nandi A, Chen Z, Patel R, Poretsky L. Polycystic ovary syndrome. Endocrinol Metab Clin North Am 2014; 43 (1): 123-47.
  16. Dewailly D. Diagnostic criteria for PCOS: need for a rethink? Best Pract Res Clin Obstet Gynaecol 2016. pii: S1521-6934(16)30008-6.
  17. Trikudanathan S. Polycystic ovarian syndrome. Med Clin North Am 2015; 99 (1): 221-35.
  18. Brassard M, Ain Melk Y, Baillargeon J.P. Basic infertility including polycystic ovary syndrome. Med Clin North Am 2008; 92 (5): 1163-92, xi.
  19. Azziz R, Carmina E, Dewailly D et al. Task force on the phenotype of the polycystic ovary syndrome of the Androgen Excess and PCOS Society: the Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91 (2): 456-88.
  20. Bremer A.A, Miller W.L. The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism of hyperandrogenemia and insulin resistance. Fertil Steril 2008; 89 (5): 1039-48.
  21. Baillargeon J.P, Nestler J.E, Ostlund R.E et al. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositol metabolism. Hum Reprod 2008; 23 (6): 1439-46.
  22. Bevilacqua A, Carlomagno G, Gerli S et al. Results from the international consensus conference on myo - inositol and D-chiro - inositol in obstetrics and gynecology - assisted reproduction technology. Gynecol Endocrinol 2015; 31 (6): 441-6.
  23. Legro R.S, Kunselman A.R, Dodson W.C, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84 (1): 165-9.
  24. Lerchbaum E, Schwetz V, Giuliani A et al. Assessment of glucose metabolism in polycystic ovary syndrome: HbAc or fasting glucose compared with the oral glucose tolerance test as a screening method. Hum Reprod 2013; 28: 2537-44.
  25. Carmina E, Oberfield S.E, Lobo R.A. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol 2010; 203 (3): 201.e1-5.
  26. Conway G.S, Dewailly D, Diamanti-Kandarakis E et al. European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group's Questionnaire. Eur J Endocrinol 2014; 171 (4): 489-98.
  27. Liodromiti S, Kelsey T.W, Anderson R.A, Nelson S.M. Can anti - Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta - analysis of extracted data. J Clin Endocrinol Metab 2013; 98 (8): 3332-40.
  28. Pellatt L, Hanna L, Brincat M et al. Granulosa cell production of anti - Mullerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 2007; 92 (1): 240-5.
  29. Gassner D, Jung R. First fully automated immunoassay for anti - Mullerian hormone. Clin Chem Lab Med 2014; 52 (8): 1143-52.
  30. Beckman Coulter. Access AMH Instructions for Use, September 2014. REFB13127.
  31. Nelson S.M, Pastuszek E, Kloss G et al. Two new automated, compared with two enzyme - linked immunosorbent, antimüllerian hormone assays. Fertil Steril 2015; 104 (4): 1016-1021.e6.
  32. Piouka A, Farmakiotis D, Katsikis I et al. Anti - Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 2009; 296 (2): E238-43.
  33. Catteau-Jonard S, Bancquart J, Poncelet E et al. Polycystic ovaries at ultrasound: normal variant or silent polycystic ovary syndrome? Ultrasound Obstet Gynecol 2012; 40 (2): 223-9.
  34. Pellatt L, Rice S, Mason H.D. Anti - Mullerian hormone and polycystic uovary syndrome: a mountain too high? Reproduction 2010; 139 (5): 825-33.
  35. Pierre A, Peigné M, Grynberg M et al. Loss of LH-induced down - regulation of anti-Mullerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome. Hum Reprod 2013; 28 (3): 762-9.
  36. Garg D, Tal R. The role of AMH in the pathophysiology of polycystic ovarian syndrome. Reprod Biomed Online 2016; 33 (1): 15-28.
  37. Cassar S, Teede H.J, Moran L.J et al. Polycystic ovary syndrome and anti - Mullerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins. Clin Endocrinol (Oxf) 2014; 81 (6): 899-906.
  38. Fonseca H.P, Brondi R.S, Piovesan F.X et al. Anti - Mullerian hormone and insulin resistance in polycystic ovary syndrome. Gynecol Endocrinol 2014; 30 (9): 667-70.
  39. Nardo L.G, Yates A.P, Roberts S.A et al. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in nonobesesubfertile women with and without polycystic ovary syndrome. Hum Reprod 2009; 24: 2917-23.
  40. Skałba P, Cygal A, Madej P et al. Is the plasma anti - Mullerian hormone (AMH) level associated with body weight and metabolic, and hormonal disturbances in women with and without polycystic ovary syndrome? Eur J Obstet Gynecol Reprod Biol 2011; 158 (2): 254-9.
  41. Caglar G.S, Kahyaoglu I, Pabuccu R et al. Anti - Mullerian hormone and insulin resistance in classic phenotype lean PCOS. Arch Gynecol Obstet 2013; 288 (4): 905-10.
  42. Mahran A, Abdelmeged A, El-Adawy A.R et al. The predictive value of circulating anti - Mullerian hormone in women with polycystic ovarian syndrome receiving clomiphene citrate: a prospective observational study. J Clin Endocrinol Metab 2013; 98 (10): 4170-5.
  43. El-Halawaty S, Rizk A, Kamal M et al. Clinical significance of serum concentration of anti - Mullerian hormone in obese women with polycystic ovary syndrome. Reprod Biomed Online 2007; 15 (5): 495-9.
  44. Vaiarelli A, Drakopoulos P, Blockeel C et al. Limited ability of circulating anti-Mü̈llerian hormone to predict dominant follicular recruitment in PCOS women treated with clomiphene citrate: a comparison of two different assays. Gynecol Endocrinol 2016; 32 (3): 227-30.
  45. Irani M, Seifer D.B, Grazi R.V et al. Vitamin D supplementation decreases TGF-beta1 bioavailability in PCOS: a randomized placebo - controlled trial. J Clin Endocrinol Metab 2015; 100 (11): 4307-14.
  46. Pinola P, Piltonen T.T, Puurunen J et al. Androgen Profile Through Life in Women With Polycystic Ovary Syndrome: A Nordic Multicenter Collaboration Study. J Clin Endocrinol Metab 2015; 100 (9): 3400-7.
  47. Daan N.M, Louwers Y.V, Koster M.P et al. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? Fertil Steril 2014; 102 (5): 1444-51.e3.
  48. Legro R.S, Arslanian S.A, Ehrmann D.A et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013; 98 (12): 4565-92.
  49. Fruzzetti F, Campagna A.M, Perini D, Carmina E. Ovarian volume in normal and hyperandrogenic adolescent women. Fertil Steril 2015; 104 (1): 196-9.
  50. Lizneva D, Suturina L, Walker W et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril 2016; 106 (1): 6-15.
  51. Hart R, Doherty D.A. The potential implications of a PCOS diagnosis on a woman’s long - term health using data linkage. J Clin Endocrinol Metab 2015; 100 (3): 911-9.
  52. Moran L.J, Hutchison S.K, Norman R.J, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011; 7: CD007506.
  53. Guzick D.S. Ovulation induction management of PCOS. Clin Obstet Gynecol 2007; 50 (1): 255-67.
  54. Fauser B.C, Tarlatzis B.C, Rebar R.W et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012; 97 (1): 28-38.e25.
  55. Spritzer P.M, Motta A.B, Sir-Petermann T, Diamanti-Kandarakis E. Novel strategies in the management of polycystic ovary syndrome. Minerva Endocrinol 2015; 40 (3): 195-212.
  56. Birch Petersen K, Pedersen N.G, Pedersen A.T et al. Mono - ovulation in women with polycystic ovary syndrome: a clinical review on ovulation induction. Reprod Biomed Online 2016; 32 (6): 563-83.
  57. Abu Hashim H, Foda O, Ghayaty E. Combined metformin - clomiphene in clomiphene - resistant polycystic ovary syndrome: a systematic review and meta - analysis of randomized controlled trials. Acta Obstet Gynecol Scand 2015; 94 (9): 921-30.
  58. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod 2008; 23 (3): 462-77.
  59. Palomba S. Aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 2015; 100 (5): 1742-7.
  60. Ecklund L.C, Usadi R.S. Endocrine and reproductive effects of polycystic ovarian syndrome. Obstet Gynecol Clin North Am 2015; 42 (1): 55-65.
  61. Deveci C.D, Demir B, Sengul O et al. Clomiphene citrate ‘stair - step’ protocol vs. traditional protocol in patients with polycystic ovary syndrome: a randomized controlled trial. Arch Gynecol Obstet 2015; 291 (1): 179-84.
  62. Li R.H, Ng E.H. Management of anovulatory infertility. Best Pract Res Clin Obstet Gynaecol 2012; 26 (6): 757-68.
  63. Abu Hashim H. Predictors of success of laparoscopic ovarian drilling in women with polycystic ovary syndrome: an evidence - based approach. Arch Gynecol Obstet 2015; 291 (1): 11-8.
  64. Legro R.S, Brzyski R.G, Diamond M.P et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 2014; 371 (2): 119-29.
  65. Palomba S, de Wilde M.A, Falbo A et al. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update 2015; 21 (5): 575-92.
  66. Palomba S, Falbo A, Chiossi G et al. Early trophoblast invasion and placentation in women with different PCOS phenotypes. Reprod Biomed Online 2014; 29 (3): 370-81.
  67. Koster M.P, de Wilde M.A, Veltman-Verhulst S.M et al. Placental characteristics in women with polycystic ovary syndrome. Hum Reprod 2015; 30 (12): 2829-37.
  68. Вarry J.A, Azizia M.M, Hardiman P.J. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta - analysis. Hum Reprod Update 2014; 20 (5): 748-58.
  69. Gottschau M, Kjaer S.K, Jensen A et al. Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study. Gynecol Oncol 2015; 136 (1): 99-103.
  70. Wang Z, Li T, Zhang W et al. Variants in DENND1A and LHCGR are associated with endometrioid adenocarcinoma. Gynecol Oncol 2012; 127 (2): 403-5.
  71. Misso M, Boyle J, Norman R, Teede H. Development of evidenced - based guidelines for PCOS and implications for community health. Semin Reprod Med 2014; 32 (3): 230-40.
  72. Yildiz B.O. Assessment, diagnosis and treatment of a patient with hirsutism. Nat Clin Pract Endocrinol Metab 2008; 4 (5): 294-300.
  73. Yildiz B.O. Approach to the patient: contraception in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2015; 100 (3): 794-802.
  74. Инструкция по применению препарата Модэлль Тренд.
  75. Инструкция по применению препарата Модэлль Пьюр.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2016

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».